Christopher Hite insider trades: Royalty Pharma (RPRX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christopher reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | RPRX | ↓ Sell | 100,000 | $58.53 | $5.9M | By SCH Investment Partners LLC | Sep 24, 2026 (2d) |
| Aug 18, 2026 | RPRX | ↓ Sell | 100,000 | $59.97 | $6.0M | By SCH Investment Partners LLC | Aug 19, 2026 (1d) |
| Jun 18, 2020 | RPRX | ↑ Buy | 70,000 | $28.00 | $2.0M | Direct | Jun 23, 2020 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RPRX insiders
Open-market trades in the last 12 months
About Christopher Hite's insider trades
Christopher Hite is EVP & Chairman, Partnering at Royalty Pharma (RPRX). Since Jun 18, 2020, Christopher has reported 1 open-market purchase worth $2.0M and 2 sales worth $11.9M on SEC Form 4. In the last 12 months: 2 sales ($11.9M).
Their filings also include grants and awards (11 filings), conversions (2 filings), other transactions (2 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RPRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.